评估在难治性或复发性B前体细胞急性淋巴细胞白血病（R/R-BCP-ALL）儿童中，短程布利纳单抗的临床疗效和安全性。于2021年8月至2022年11月间，回顾性收集和分析了33名接受短程布利纳单抗治疗（14天）的R/R BCP-ALL患儿（年龄0-18岁）的临床数据。在33名BCP-ALL患者中，26名患者达到完全缓解（CR），总缓解率为78.8%（26/33）。缓解持续时间约为14天。7名未达到CR的儿童中，5名在28天仍处于缓解状态。11名难治性疾病患者和22名复发性疾病患者中，缓解率分别为90.9%（10/11）和72.7%（16/22）。26名CR患者和7名未达到CR的患者的总生存率（OS）分别为96.1%和57.1%（p = 0.002），无病生存率（DFS）分别为96.1%和42.9%（p < 0.001）。在26名CR患者中，15名接受了造血干细胞移植（HSCT）和11名未接受HSCT；其OS分别为93.3%和100%（p = 0.40），DFS分别为93.3%和100%（p = 0.400）。所有患者的总体生存率（OS）为87.9%（29/33），DFS为84.8%（28/33）。共有18例（54.5%）细胞因子释放综合征（CRS），2例（6.1%）严重CRS（均为3级），1例（3.0%）免疫效应细胞相关的神经毒性综合征（ICANS），0例（0%）ICANS ≥ 3级，无因治疗导致的死亡。短期随访显示，在接受短程布利纳单抗治疗的儿童中，R/R BCP-ALL的缓解率较高。毒性低且可控。在布利纳单抗桥接HSCT后没有观察到明显的短期生存优势。在发展中国家，短程布利纳单抗可以取得满意的疗效，同时减少家庭开支并节约医疗资源。© 2023 Xie, Liu, Zhou, Wang, He, Xiao, Hu and Lu.

To evaluate the clinical efficacy and safety of a short course of blinatumomab in children with refractory or relapsed precursor B-cell acute lymphoblastic leukemia (R/R-BCP-ALL).The clinical data of 33 R/R BCP-ALL children aged 0-18 years who underwent a short course of blinatumomab (14 days) between August 2021 and November 2022 were retrospectively collected and analyzed.Among 33 patients with BCP-ALL, 26 achieved complete remission (CR), with a total remission rate of 78.8% (26/33). The duration of remission was approximately 14 days. Of the 7 children without CR, 5 were still in remission at 28 days. In 11 patients with refractory disease and 22 with recurrence, the remission rates were 90.9% (10/11) and 72.7% (16/22), respectively. The overall survival (OS) rates of the 26 patients with CR and seven patients without CR were 96.1% and 57.1% (p = 0.002), respectively, and the disease-free survival (DFS) rates were 96.1% and 42.9% (p < 0.001), respectively. Among the 26 patients with CR, 15 underwent bridging hematopoietic stem cell transplantation (HSCT) and 11 did not receive HSCT; with OS rates of 93.3% and 100% (p = 0.40) and DFS rates of 93.3% and 100% (p = 0.400), respectively. The OS for all patients was 87.9% (29/33) and the DFS was 84.8% (28/33). There were 18 cases (54.5%) of cytokine release syndrome (CRS), 2 cases (6.1%) of severe CRS (all grade 3), 1 case (3.0%) of immune effector cell-associated neurotoxicity syndrome (ICANS), 0 cases (0%) of ICANS ≥ grade 3, and no deaths caused by treatment.Short-term follow-up revealed a high R/R BCP-ALL remission rate in children treated with a short course of blinatumomab. The toxicity was low and controllable. No significant short-term survival benefits were observed after bridging HSCT with blinatumomab. In developing countries, a short course of blinatumomab can achieve satisfactory outcomes, while reducing household costs and saving medical resources.© 2023 Xie, Liu, Zhou, Wang, He, Xiao, Hu and Lu.